An Act to amend the Code of Virginia by adding a section numbered 38.2-3407.15:9, relating to health insurance; limit on cost-sharing payments for prescription drugs under certain plans.
HB625 adds a new section to Virginia insurance law requiring certain health plans in the individual and small group markets to cap a covered person’s out-of-pocket cost-sharing for prescription drugs. For each metal tier, at least one plan offered by a carrier in each rating area must limit prescription drug cost-sharing to no more than $150 per 30-day supply in platinum plans, $200 in gold plans, $250 in silver plans, and $300 in bronze plans. These limits apply regardless of whether the enrollee has met a deductible.
The bill also requires any plan offered to satisfy these requirements to be clearly named and marketed like other plans, and it prevents such plans from counting against any plan-option limits set by the State Corporation Commission or the Virginia Health Benefits Exchange. It includes an exception for health savings account-qualified high deductible health plans if applying the cost-sharing limits would interfere with federal HSA eligibility rules, in which case the deductible-related requirements do not apply until the federal minimum deductible is met. The act applies to policies, subscription contracts, and health care plans issued, delivered, or renewed on and after January 1, 2028.
The bill amends the Code of Virginia by creating § 38.2-3407.15:9 and directly regulates health insurance benefit design in the individual and small group markets. It imposes new carrier obligations regarding prescription drug cost-sharing, plan labeling, and plan availability, while preserving compliance with federal HSA-qualified high deductible health plan rules. The practical effect is to require insurers to offer at least one plan per metal level in each rating area with capped prescription drug out-of-pocket costs, which may affect premiums, plan design, and consumer choice in the Virginia marketplace.
The available record shows no committee transcripts or recorded votes, so there is no documented debate to gauge detailed support or opposition. Based on the enacted chapter status, the bill ultimately passed and was signed into law, suggesting sufficient legislative support. The policy itself reflects a consumer-protection approach aimed at lowering prescription drug costs, which is generally associated with favorable sentiment among supporters of expanded affordability and access.
The main likely point of contention is the balance between lowering prescription drug costs for consumers and preserving insurer flexibility in plan design and pricing. Insurers or market administrators could be concerned about the mandated cost-sharing caps, the requirement to offer at least one compliant plan in each metal tier and rating area, and the potential effect on premiums or plan availability. Another possible issue is the interaction with federal HSA-qualified high deductible health plan rules, which the bill addresses by carving out an exception until the federal minimum deductible is met.